A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

  • Breast Cancer HER-2 Positive
Trial Status:

Completed

This trial runs in
Countries
  • Algeria
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • China
  • Ecuador
  • Egypt
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • Israel
  • Italy
  • Lebanon
  • Lithuania
  • Mexico
  • Morocco
  • Netherlands
  • pakistan
  • Peru
  • Poland
  • Portugal
  • Saudi Arabia
  • Serbia
  • Slovenia
  • Spain
  • Sweden
  • Turkey
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • Uruguay
  • venezuela
Trial Identifier:

NCT01572038 2011-005334-20 MO28047

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line treatment in participants with metastatic or locally recurrent HER2-positive breast cancer. Participants will receive pertuzumab intravenously (IV) and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT01572038 , MO28047 , 2011-005334-20 Trial Identifier
      Docetaxel, Nab-paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab Treatments
      Breast Neoplasms Condition
      Official Title

      A Multicenter, Open-Label, Single-Arm Study of Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Histologically or cytologically confirmed adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection
      • HER2-positive breast cancer
      • Eastern cooperative Oncology Group (ECOG) performance status 0, 1 or 2
      • LVEF of at least 50 percent (%)
      Exclusion Criteria
      • Previous systemic non-hormonal anti-cancer therapy for metastatic or locally recurrent disease
      • Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence less than or equal to (</=) 6 months
      • Previous approved or investigative anti-HER2 agents in any breast cancer treatment setting, except for trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
      • Disease progression while receiving trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
      • History of persistent Grade 2 or higher (National Cancer Institute Common Toxicity Criteria [NCI-CTC], Version 4.0) hematological toxicity resulting from previous adjuvant or neoadjuvant therapy
      • Central nervous system (CNS) metastases
      • Current peripheral neuropathy of Grade 3 or greater (NCI-CTC, version 4.0)
      • History of other malignancy within the last 5 years prior to first study drug administration, except for carcinoma in situ of the cervix or basal cell carcinoma
      • Inadequate bone marrow, liver or renal function
      • Uncontrolled hypertension
      • Hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now